Product Description
AZD3839 is a brain-permeable inhibitor of human BACE1 (nonselective for BACE1 vs BACE2) that has been shown to reduce levels of Abeta1-40 and Abeta1-42 in in vitro models. (Sourced from: https://openinnovation.astrazeneca.com/preclinical-research/preclinical-molecules/azd3839.html)
Mechanisms of Action: BACE1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01348737 |
D4080C00001 | P1 |
Completed |
Alzheimer Disease |
2011-11-01 |
2019-03-19 |
Treatments |